- The European Commission has approved Janssen's, a unit of Johnson & Johnson JNJ Ponvory (ponesimod), to treat adult patients with relapsing multiple sclerosis.
- The EC approval of ponesimod is based on data from the Phase 3 OPTIMUM trial that met the primary endpoint of annualized relapse rate (ARR), with a rate reduction of 30.5% compared with teriflunomide.
- Ponesimod also showed statistically significant superiority on one of the secondary endpoints, combined unique active lesions, and reduced the number of new inflammatory lesions on brain MRI by 56% at week 108 compared to teriflunomide.
- The treatment had won FDA approval in March.
- Price Action: JNJ shares are down 0.20% at $170.62 during the market session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
